Terns Pharmaceuticals (NASDAQ: TERN) has announced a significant setback in its drug development efforts, deciding to discontinue the oral GLP-1 receptor agonist, TERN-601, intended for weight...
Recent advancements in mitochondrial therapy are showing promise for treating diseases linked to mitochondrial dysfunction, which affects numerous bodily systems. One notable player in this field...